<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04557384</url>
  </required_header>
  <id_info>
    <org_study_id>17800</org_study_id>
    <secondary_id>I4T-MC-JVDU</secondary_id>
    <nct_id>NCT04557384</nct_id>
  </id_info>
  <brief_title>A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in participants with advanced cancer is to learn more about the&#xD;
      safety of ramucirumab when given by injection under the skin (subcutaneous injection). The&#xD;
      study will also measure how much ramucirumab gets into the bloodstream and how long it takes&#xD;
      the body to get rid of it.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to a business decision&#xD;
  </why_stopped>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Actual">May 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Ramucirumab</measure>
    <time_frame>Cycle 1 Day 1 through End of Treatment (Estimated up to 10 Months)</time_frame>
    <description>PK: AUC of Ramucirumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of Ramucirumab</measure>
    <time_frame>Cycle 1 Day 1 through End of Treatment (Estimated up to 10 Months)</time_frame>
    <description>PK: Cmax of Ramucirumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Serum Trough Concentration (Ctrough) of Ramucirumab</measure>
    <time_frame>Cycle 1 Day 1 through End of Treatment (Estimated up to 10 Months)</time_frame>
    <description>Ctrough of Ramucirumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Ramucirumab Antibodies</measure>
    <time_frame>Cycle 1 Day 1 through End of Treatment (Estimated up to 10 Months)</time_frame>
    <description>Percentage of Participants with Anti-Ramucirumab Antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Injection Site Reactions (ISRs)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 3 Day 21 (21 Day Cycles)</time_frame>
    <description>Percentage of Participants with ISRs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Ramucirumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab given subcutaneously (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Ramucirumab</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1&#xD;
             (RECIST 1.1).&#xD;
&#xD;
          -  In the judgment of the investigator, be an appropriate candidate for experimental&#xD;
             therapy and:&#xD;
&#xD;
               -  For Cohort A only: Have exhausted all anticancer treatments with proven clinical&#xD;
                  benefit OR&#xD;
&#xD;
               -  For Cohorts B and C only: Must have one of the three conditions below:&#xD;
&#xD;
                    -  Have exhausted all anti-cancer treatments with proven clinical benefit, OR&#xD;
&#xD;
                    -  Have hepatocellular carcinoma or gastric cancer who have received prior&#xD;
                       treatment, and where IV ramucirumab monotherapy is clinically acceptable&#xD;
                       treatment after progression OR&#xD;
&#xD;
                    -  Have a diagnosis for which IV ramucirumab in combination with additional&#xD;
                       anticancer therapy is clinically acceptable treatment&#xD;
&#xD;
                    -  Additionally, it must be clinically acceptable to delay initiation of the&#xD;
                       combination partner for 3 weeks from the initiation of ramucirumab dosing.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status score of 0 or 1.&#xD;
&#xD;
          -  Have discontinued all previous treatments for cancer with adequate wash-out period and&#xD;
             recovered from the acute effects of therapy.&#xD;
&#xD;
          -  Have adequate hematologic, hepatic, and renal functions and electrolytes.&#xD;
&#xD;
          -  Males and females of child-bearing potential must agree to use highly effective&#xD;
             contraceptive methods during study treatment and for at least 84 days/12 weeks&#xD;
             following the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have uncontrolled hypertension defined as systolic blood pressure (BP) &gt;150 mmHg or&#xD;
             diastolic BP &gt;90 mmHg despite standard medical management.&#xD;
&#xD;
          -  Have significant bleeding disorders or experienced Grade 3/4 gastrointestinal (GI)&#xD;
             bleeding within 3 months prior to enrollment.&#xD;
&#xD;
          -  Have hepatic impairment (such as severe liver cirrhosis Child-Pugh B [or worse],&#xD;
             cirrhosis with a history of hepatic encephalopathy, clinically meaningful ascites&#xD;
             requiring ongoing treatment with diuretics and/or paracentesis, or history of&#xD;
             hepatorenal syndrome).&#xD;
&#xD;
          -  Have experienced any arterial thromboembolic events (ATEs), including but not limited&#xD;
             to myocardial infarction, transient ischemic attack, cerebrovascular accident, or&#xD;
             unstable angina, ≤6 months prior to randomization.&#xD;
&#xD;
          -  The participant has clinically relevant congestive heart failure (CHF; New York Heart&#xD;
             Association [NYHA] Grade ≥2) or symptomatic or poorly controlled cardiac arrhythmia.&#xD;
&#xD;
          -  Have symptomatic central nervous system (CNS) metastases. Screening is not required.&#xD;
&#xD;
          -  Have history of GI perforation and/or fistula within 6 months prior to enrollment.&#xD;
&#xD;
          -  Have an active uncontrolled systemic bacterial, viral, or fungal infection or serious&#xD;
             ongoing uncontrolled intercurrent illness.&#xD;
&#xD;
          -  Have a serious or non-healing wound, ulcer, or bone fracture within 4 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Have received IV ramucirumab in the past.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology West</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute- Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka Sayama-shi</city>
        <state>Osaka</state>
        <zip>589 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1KS07d3wTANvMFupLlEcxL</url>
    <description>A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

